Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

  • This share is currently suspended. It was suspended at a price of 5.375

Share Price Information for Iconic Labs (ICON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.375
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5.375
ICON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Response to Announcement by OTT Holdings

18 Jan 2021 07:00

RNS Number : 9373L
Iconic Labs PLC
18 January 2021
 

 

 

 

 

Iconic Labs Plc ("Iconic Labs" or the "Company")

 

Board Response to Announcement made by OTT Holdings

 

Iconic Labs Plc (LSE:ICON), a multidivisional new media and technology business, notes the content of a press release issued by OTT Holdings Limited ("OTT Holdings") on 15 January 2021 ("Press Release") which makes various allegations against the Company and its board of directors ("Board").

 

The Board do not accept the allegations and assertions made in the Press Release which are wholly denied and wish to draw shareholders attention to the following points:

 

· To date the Company has not received a valid requisition notice to convene a general meeting

· The Board has not called a general meeting of its shareholders and no general meeting is scheduled to take place

· Notwithstanding OTT Holding's claim in the Press Release, that they are the "holder of 5,735,555,554 shares" in the Company, OTT Holdings is not registered as a holder of any shares in the Company by the Company's share registrar

· Initial enquiries suggest that OTT Holdings is a Cyprus based developer of hotels, and which does not appear to have any commercial interest or experience in the social media and publishing industry in which the Company conducts its operations

· As part of the process of being satisfied as to who is the ultimate owner of these shares (and whether there are any connected parties acting in concert), the Company is seeking to clarify how the ultimate owner of these shares acquired them, on what basis and whether they are acting in concert with other shareholders

 

Further, the Board notes the allegations made by OTT Holdings in the Press Release concerning an alleged lack of commercial progress which is completely refuted by the Board. The Company has continued to make substantial progress in increasing the revenues and developing the operations of the Company, enabling it to move towards its aim of being profitable. In the last 22 months the Board has had to restructure the previous WideCells business that was close to insolvency and has built a new media business from zero revenues to now running at an annual revenue run rate of over £1m a year. The large majority of these revenues come from management service agreements which Iconic was only able to obtain because of the skills and experience of the Board in managing digital media businesses. It should also be noted that during the last 20 months, the Board members and the Company's advisors have deferred substantial parts of their salaries and fees in order to invest in the growth of the Company.

 

The Company agrees that OTT is correct in identifying that the involvement of European High Growth Opportunities Securitization Fund ("EHGOF") in the Company pre-dates the involvement of any of the current board members or David Sefton.

 

 

It is also noted that the Board inherited the convertible financing structure put in place by the previous management team with EHGOF and subsequently the Board has been very clear that it believes the share price of the Company has been negatively affected by this type of facility

 

The facility with EHGOF was terminated by the Company when EHGOF refused to provide the investment monies due under a loan note for which it had subscribed. The Company considers the obligation to provide investment monies was, following a subscription for the loan notes by EHGOF, unconditional and was the sole purpose of the Company entering into the facility. This followed several instances of EHGOF being late in providing investment monies when obliged to do so, but the Company does not know the reason why monies were being withheld by EHGOF. Following the termination of the facility with EHGOF, Alpha Blue Ocean ("ABO"), on behalf of EHGOF, then, in the Company's view, reneged on an agreement in principle for settlement of all outstanding loan notes. The Company has always been and remains open to reaching a settlement agreement with EHGOF on commercially practical and sensible terms.

 

The Board is aware that if the proposals referred to in the OTT Holdings Press Release in respect of changing the composition of the Board at a general meeting were ever to be effected, this would give Greencastle Capital a right (which it can exercise at its sole discretion) to terminate either or both of the management services agreements that exist between Greencastle Capital and the Company, and which are in respect of the JOE Media and TheLondonEconomic businesses. Given that the management services agreements constitute the large majority of the revenues the Board does not believe this would be in the best interests of its shareholders as a whole.

 

It should be noted that the Board is united in respect of these matters and were the proposals suggested by OTT Holdings in its Press Release as to the changing of the composition of the Board to be effected then all of the members of the Board would resign.

 

Finally, despite the allegations made by OTT Holdings in the Press Release, the Board remains resolute that it will seek to act in the best interests of its shareholders and stakeholders as a whole. For the avoidance of any doubt, the Board as a collective will seek to protect the reputation of the Company and its Board and take all actions that are necessary to do so.

 

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information for the purposes of the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

**ENDS**

For further information, please visit the Company's website www.iconiclabs.co.uk or contact:

Damon Heath

Shard Capital Partners LLP

Tel: +44 (0) 20 7186 9950

Iconic Labs ir@iconiclabs.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUBVKRAUUAAAR
Date   Source Headline
1st May 20187:02 amRNSAnnual Accounts and Fundraising Update
26th Mar 20187:00 amRNSLandmark deal to launch CellPlan insurance in Asia
19th Mar 20187:00 amRNSGranted Innovate UK KTP for Stem Cell Research
27th Feb 20187:00 amRNSLicence Award from the Human Tissue Authority
19th Feb 20187:00 amRNSBoard Changes and Launch of Wideacademy Platform
21st Dec 20177:00 amRNSCorporate Update
2nd Nov 20177:00 amRNSRevenue generation with White Apex agreement
12th Oct 20177:00 amRNSCellPlan expansion, e-commerce platform launch UK
11th Oct 20177:00 amRNSPartner Secured to Expand into MENA & Asia-Pacific
29th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSWideacademy Update, Presenting at Investor Event
15th Aug 20177:00 amRNSRaises £750,000 to support Company's divisions
31st Jul 20177:00 amRNSResearch Licence Granted from HTA
24th Jul 20177:00 amRNSNew product to target the dental market
21st Jul 20177:00 amRNSCellPlan launches E-Commerce Platform in the UK
12th Jul 20177:00 amRNSCorporate Charity Commitment
4th Jul 20177:00 amRNSAgreement to Roll Out CellPlan in Brazil
3rd Jul 20177:00 amRNSInvestor Evening and CFO Now Employed Full-time
27th Jun 20177:00 amRNSRevenue with launch of CellPlan
22nd Jun 20173:30 pmRNSResults of AGM
22nd Jun 20177:00 amRNSAGM Statement and Notice of Investor Evening
12th Jun 20177:00 amRNSWideAcademy Strategic Update
6th Jun 20177:00 amRNSLaunch of CellPlan set to generate maiden revenues
2nd Jun 20177:00 amRNSWideCells Named 21st in Global DISRUPT 100 List
23rd May 20177:00 amRNSAttendance at British Dental Conference
15th May 20177:00 amRNSAttendance at Brazilian Conference
4th May 20172:15 pmRNSHolding(s) in Company
2nd May 20177:40 amRNSPosting of Report and Accounts and Notice of AGM
12th Apr 20171:00 pmRNSPlacing
30th Mar 20177:00 amRNSPreliminary Results
16th Feb 20177:00 amRNSBoard Appointment
31st Jan 20177:00 amRNSDirector Purchases and Grant of Options
30th Jan 20174:40 pmRNSSecond Price Monitoring Extn
30th Jan 20174:35 pmRNSPrice Monitoring Extension
26th Jan 201710:30 amRNSGrant of Options
24th Jan 20177:00 amRNSExtends CellPlan Roll Out & New Product Launch
9th Jan 20177:00 amRNSDefinitive Agreement with BioVault for CellPlan
30th Nov 20167:00 amRNSNew Revenue Stream: Stem Cell Research, Manchester
7th Nov 20167:00 amRNSLOI with 1st Cord Blood Bank to Roll Out CellPlan
24th Oct 20167:00 amRNSCorporate Update
10th Oct 20167:00 amRNSUpdate on CellPlan
27th Sep 20167:00 amRNSPartners with University of Westminster
5th Sep 20167:00 amRNSLaunches WideCells Brasil
12th Aug 20167:00 amRNSHoldings In Company
5th Aug 20167:00 amRNSUpdate on Manchester Facility and Appointments
27th Jul 20168:00 amRNSPlacing & First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.